Isoquercitrin, ingredients in Tetrastigma hemsleyanum Diels et Gilg, inhibits hepatocyte growth factor/scatter factor-induced tumor cell migration and invasion

References

• Naldini L, Vigna E, Ferracini R, et al. The tyrosine kinase encoded by the MET proto-oncogene is activated by autophosphorylation. Mol Cell Biol. 1991;11(4):1793–1803. doi:10.1128/MCB.11.4.1793.
   PubMed Web of Science ®Google Scholar
• Park WS, Dong SM, Kim SY, et al. Somatic mutations in the kinase domain of the Met/hepatocyte growth factor receptor gene in childhood hepatocellular carcinomas. Cancer Res. 1999;59(2):307–310.
   PubMed Web of Science ®Google Scholar
• Bottaro DP, Rubin JS, Faletto DL, et al. Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science. 1991;251(4995):802–804. doi:10.1126/science.1846706.
   PubMed Web of Science ®Google Scholar
• Nakamura T, Teramoto H, Ichihara A. Purification and characterization of a growth factor from rat platelets for mature parenchymal hepatocytes in primary cultures. Proc Natl Acad Sci U S A. 1986;83(17):6489–6493. doi:10.1073/pnas.83.17.6489.
   PubMed Web of Science ®Google Scholar
• Stoker M, Gherardi E, Perryman M, et al. Scatter factor is a fibroblast-derived modulator of epithelial cell mobility. Nature. 1987;327(6119):239–242. doi:10.1038/327239a0.
   PubMed Web of Science ®Google Scholar
• Bussolino F, Di Renzo MF, Ziche M, et al. Hepatocyte growth factor is a potent angiogenic factor which stimulates endothelial cell motility and growth. J Cell Biol. 1992;119(3):629–641. doi:10.1083/jcb.119.3.629.
   PubMed Web of Science ®Google Scholar
• Tsarfaty I, Resau JH, Rulong S, et al. The met proto-oncogene receptor and lumen formation. Science. 1992;257(5074):1258–1261. doi:10.1126/science.1387731.
   PubMed Web of Science ®Google Scholar
• Jeffers M, Rong S, Vande Woude GF. Hepatocyte growth factor/scatter factor-Met signaling in tumorigenicity and invasion/metastasis. J Mol Med (Berl). 1996;74(9):505–513. doi:10.1007/BF00204976.
   PubMed Web of Science ®Google Scholar
• Birchmeier W, Brinkmann V, Niemann C, et al. Role of HGF/SF and c-Met in morphogenesis and metastasis of epithelial cells. Ciba Found Symp. 1997;212:230–240. discussion 240-236.
   PubMedGoogle Scholar
• Schmidt L, Duh FM, Chen F, et al. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet. 1997;16(1):68–73. doi:10.1038/ng0597-68.
   PubMed Web of Science ®Google Scholar
• Lee JH, Han SU, Cho H, et al. A novel germ line juxtamembrane Met mutation in human gastric cancer. Oncogene. 2000;19(43):4947–4953. doi:10.1038/sj.onc.1203874.
   PubMed Web of Science ®Google Scholar
• Jiang WG, Martin TA, Parr C, et al. Hepatocyte growth factor, its receptor, and their potential value in cancer therapies. Crit Rev Oncol Hematol. 2005;53(1):35–69. doi:10.1016/j.critrevonc.2004.09.004.
   PubMed Web of Science ®Google Scholar
• Michieli P, Mazzone M, Basilico C, et al. Targeting the tumor and its microenvironment by a dual-function decoy Met receptor. Cancer Cell. 2004;6(1):61–73. doi:10.1016/j.ccr.2004.05.032.
   PubMed Web of Science ®Google Scholar
• Ono T, Tsuji T, Sakai M, et al. Induction of hepatocyte growth factor production in human dermal fibroblasts and their proliferation by the extract of bitter melon pulp. Cytokine. 2009;46(1):119–126. doi:10.1016/j.cyto.2008.12.016.
   PubMed Web of Science ®Google Scholar
• Jiang WG, Ye L, Ruge F, et al. YangZheng XiaoJi exerts anti-tumour growth effects by antagonising the effects of HGF and its receptor, cMET, in human lung cancer cells. J Transl Med. 2015;13:280. doi:10.1186/s12967-015-0639-1.
   PubMed Web of Science ®Google Scholar
• Xiong Y, Wu X, Rao L. Tetrastigma hemsleyanum (Sanyeqing) root tuber extracts induces apoptosis in human cervical carcinoma HeLa cells. J Ethnopharmacol. 2015;165:46–53. doi:10.1016/j.jep.2015.02.030.
   PubMed Web of Science ®Google Scholar
• Peng X, Zhuang DD, Guo QS. Induction of S phase arrest and apoptosis by ethyl acetate extract from Tetrastigma hemsleyanum in human hepatoma HepG2 cells. Tumour Biol. 2015;36(4):2541–2550. doi:10.1007/s13277-014-2869-x.
   PubMedGoogle Scholar
• Feng Z, Hao W, Lin X, et al. Antitumor activity of total flavonoids from Tetrastigma hemsleyanum Diels et Gilg is associated with the inhibition of regulatory T cells in mice. Onco Targets Ther. 2014;7:947–956.
   PubMed Web of Science ®Google Scholar
• Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer. 2002;2(6):442–454. doi:10.1038/nrc822.
   PubMed Web of Science ®Google Scholar
• Zhou W, Thiery JP. Loss of Git2 induces epithelial-mesenchymal transition by miR146a-Cnot6L-controlled expression of Zeb1. J Cell Sci. 2013;126(Pt 12):2740–2746. doi:10.1242/jcs.126367.
   PubMed Web of Science ®Google Scholar
• Zhou W, Ye XL, Xu J, et al. The lncRNA H19 mediates breast cancer cell plasticity during EMT and MET plasticity by differentially sponging miR-200b/c and let-7b. Sci Signal. 2017;10(483): doi:10.1126/scisignal.aak9557.
   Web of Science ®Google Scholar
• Jo E, Park SJ, Choi YS, et al. Kaempferol Suppresses Transforming Growth Factor-beta1-Induced Epithelial-to-Mesenchymal Transition and Migration of A549 Lung Cancer Cells by Inhibiting Akt1-Mediated Phosphorylation of Smad3 at Threonine-179. Neoplasia. 2015;17(7):525–537. doi:10.1016/j.neo.2015.06.004.
   PubMed Web of Science ®Google Scholar
• Bhat FA, Sharmila G, Balakrishnan S, et al. Quercetin reverses EGF-induced epithelial to mesenchymal transition and invasiveness in prostate cancer (PC-3) cell line via EGFR/PI3K/Akt pathway. J Nutr Biochem. 2014;25(11):1132–1139. doi:10.1016/j.jnutbio.2014.06.008.
   PubMed Web of Science ®Google Scholar
• Zhu Y, Wu J, Li S, et al. Apigenin inhibits migration and invasion via modulation of epithelial mesenchymal transition in prostate cancer. Mol Med Rep. 2015;11(2):1004–1008. doi:10.3892/mmr.2014.2801.
   PubMed Web of Science ®Google Scholar
• Cao B, Su Y, Oskarsson M, et al. Neutralizing monoclonal antibodies to hepatocyte growth factor/scatter factor (HGF/SF) display antitumor activity in animal models. Proc Natl Acad Sci U S A. 2001;98(13):7443–7448. doi:10.1073/pnas.131200498.
   PubMed Web of Science ®Google Scholar
• Abounader R, Ranganathan S, Lal B, et al. Reversion of human glioblastoma malignancy by U1 small nuclear RNA/ribozyme targeting of scatter factor/hepatocyte growth factor and c-met expression. J Natl Cancer Inst. 1999;91(18):1548–1556. doi:10.1093/jnci/91.18.1548.
   PubMedGoogle Scholar
• Abounader R, Lal B, Luddy C, et al. In vivo targeting of SF/HGF and c-met expression via U1snRNA/ribozymes inhibits glioma growth and angiogenesis and promotes apoptosis. FASEB J. 2002;16(1):108–110. doi:10.1096/fj.01-0421fje.
   PubMed Web of Science ®Google Scholar
• Guerin C, Luddy C, Abounader R, et al. Glioma inhibition by HGF/NK2, an antagonist of scatter factor/hepatocyte growth factor. Biochem Biophys Res Commun. 2000;273(1):287–293. doi:10.1006/bbrc.2000.2935.
   PubMed Web of Science ®Google Scholar
• Brockmann MA, Papadimitriou A, Brandt M, et al. Inhibition of intracerebral glioblastoma growth by local treatment with the scatter factor/hepatocyte growth factor-antagonist NK4. Clin Cancer Res. 2003;9(12):4578–4585.
   PubMed Web of Science ®Google Scholar
• Christensen JG, Schreck R, Burrows J, et al. A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo. Cancer Res. 2003;63(21):7345–7355.
   PubMed Web of Science ®Google Scholar
• Sattler M, Pride YB, Ma P, et al. A novel small molecule met inhibitor induces apoptosis in cells transformed by the oncogenic TPR-MET tyrosine kinase. Cancer Res. 2003;63(17):5462–5469.
   PubMed Web of Science ®Google Scholar
• Wang SY, Chen B, Zhan YQ, et al. SU5416 is a potent inhibitor of hepatocyte growth factor receptor (c-Met) and blocks HGF-induced invasiveness of human HepG2 hepatoma cells. J Hepatol. 2004;41(2):267–273. doi:10.1016/j.jhep.2004.04.013.
   PubMed Web of Science ®Google Scholar
• Razavi SM, Zahri S, Zarrini G, et al. Biological activity of quercetin-3-O-glucoside, a known plant flavonoid. Bioorg Khim. 2009;35(3):414–416.
   PubMedGoogle Scholar
• Rogerio AP, Kanashiro A, Fontanari C, et al. Anti-inflammatory activity of quercetin and isoquercitrin in experimental murine allergic asthma. Inflamm Res. 2007;56(10):402–408. doi:10.1007/s00011-007-7005-6.
   PubMed Web of Science ®Google Scholar
• Li R, Yuan C, Dong C, et al. In vivo antioxidative effect of isoquercitrin on cadmium-induced oxidative damage to mouse liver and kidney. Naunyn Schmiedebergs Arch Pharmacol. 2011;383(5):437–445. doi:10.1007/s00210-011-0613-2.
   PubMed Web of Science ®Google Scholar
• Jung SH, Kim BJ, Lee EH, et al. Isoquercitrin is the most effective antioxidant in the plant Thuja orientalis and able to counteract oxidative-induced damage to a transformed cell line (RGC-5 cells). Neurochem Int. 2010;57(7):713–721. doi:10.1016/j.neuint.2010.08.005.
   PubMed Web of Science ®Google Scholar
• Chen Q, Li P, Li P, et al. Isoquercitrin inhibits the progression of pancreatic cancer in vivo and in vitro by regulating opioid receptors and the mitogen-activated protein kinase signalling pathway. Oncol Rep. 2015;33(2):840–848. doi:10.3892/or.2014.3626.
   PubMed Web of Science ®Google Scholar
• Amado NG, Predes D, Fonseca BF, et al. Isoquercitrin suppresses colon cancer cell growth in vitro by targeting the Wnt/beta-catenin signaling pathway. J Biol Chem. 2014;289(51):35456–35467. doi:10.1074/jbc.M114.621599.
   PubMed Web of Science ®Google Scholar
• Huang G, Tang B, Tang K, et al. Isoquercitrin inhibits the progression of liver cancer in vivo and in vitro via the MAPK signalling pathway. Oncol Rep. 2014;31(5):2377–2384. doi:10.3892/or.2014.3099.
   PubMed Web of Science ®Google Scholar
• Zhou J, Yoshitomi H, Liu T, et al. Isoquercitrin activates the AMP-activated protein kinase (AMPK) signal pathway in rat H4IIE cells. BMC Complement Altern Med. 2014;14:42. doi:10.1186/1472-6882-14-42.
   PubMed Web of Science ®Google Scholar